Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-Term Debt issuances (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Short-Term Debt issuances for 5 consecutive years, with -$5.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-Term Debt issuances fell 2147.29% to -$5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 69.56% increase, with the full-year FY2025 number at $6.7 million, up 701.44% from a year prior.
  • Short-Term Debt issuances was -$5.8 million for Q4 2025 at Aytu Biopharma, down from $5.8 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $42.2 million in Q3 2021 to a low of -$43.0 million in Q4 2021.
  • A 5-year average of $63388.9 and a median of $119500.0 in 2022 define the central range for Short-Term Debt issuances.
  • Peak YoY movement for Short-Term Debt issuances: plummeted 2165.42% in 2023, then surged 983.96% in 2025.
  • Aytu Biopharma's Short-Term Debt issuances stood at -$43.0 million in 2021, then surged by 98.47% to -$658000.0 in 2022, then surged by 71.28% to -$189000.0 in 2023, then tumbled by 36.51% to -$258000.0 in 2024, then plummeted by 2147.29% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Short-Term Debt issuances are -$5.8 million (Q4 2025), $5.8 million (Q3 2025), and -$965000.0 (Q2 2025).